Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

533717 GLS1 Inhibitor III, CB-839 - CAS 1439399-58-2 - Calbiochem

Cell-permeable, orally available, potent, selective & non-competitive GLS1 inhibitor. Reduces glutamine consumption & glutamate secretion, and induces apoptosis.

MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: N-(6-(4-(5-((2-Pyridin-2-ylacetyl)amino)-1,3,4-thiadiazol-2-yl)butyl)pyridazin-3-yl)-2-(3-(trifluoromethoxy)phenyl)acetamide, KGA Inhibitor III, 2-(Pyridin-2-yl)-N-(5-(4-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido)pyridazin-3-yl)butyl)-1,3,4-thiadiazol-2-yl)acetamide, GAC Inhibitor III, Kidney-Type Glutaminase Inhibitor III

Primary Target: GLS1
533717
Purchase on Sigma-Aldrich

Overview

Replacement Information

Key Spec Table

CAS #Empirical Formula
1439399-58-2C₂₆H₂₄F₃N₇O₃S

Products

Catalogue NumberPackaging Qty/Pack
5.33717.0001 Glass bottle 10 mg
Description
OverviewA cell-permeable, orally available thiadiazolyl-butyl-pyridazinyl compound that acts as a potent, selective, time-dependent, and slowly-reversible (t1/2 = 45 min at 25 °C) inhibitor of glutaminase (IC50 = 45, 23 and 28 nM for rec hu-GAC, KGA and GAC, respectively). The inhibition appears to be non-competitive and allosteric. Exhibits anti-proliferative effects in HCC1806 and MDA-MB-231 triple-negative breast cancer cell lines (IC50 = 49 and 26 nM, respectively), but does not affect the viability of ER+/HER2-T47D cell line. Shown to reduce glutamine consumption (IC50 = 17 nM) and glutamate production (IC50 = 15 nM) rates in HCC1806 cells. Inhibits the growth of HCC1806 xenografts in mice (~200 mg/kg, p.o., b.i.d) and of JIMT-1 xenografts (200 mg/kg p.o., b.i.d), either alone or in combination with paclitaxel (10 mg/kg , 5 doses alternate days).

Please note that the molecular weight for this compound is batch-specific due to variable water content. Please refer to the vial label or the certificate of analysis for the batch-specific molecular weight. The molecular weight provided represents the baseline molecular weight without water.
Catalogue Number533717
Brand Family Calbiochem®
SynonymsN-(6-(4-(5-((2-Pyridin-2-ylacetyl)amino)-1,3,4-thiadiazol-2-yl)butyl)pyridazin-3-yl)-2-(3-(trifluoromethoxy)phenyl)acetamide, KGA Inhibitor III, 2-(Pyridin-2-yl)-N-(5-(4-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido)pyridazin-3-yl)butyl)-1,3,4-thiadiazol-2-yl)acetamide, GAC Inhibitor III, Kidney-Type Glutaminase Inhibitor III
DescriptionGLS1 Inhibitor III, CB-839
References
ReferencesGross, M.I., et al. 2014. Mol. Cancer Ther. 13, 890.
Product Information
CAS number1439399-58-2
FormYellow to brown solid
Hill FormulaC₂₆H₂₄F₃N₇O₃S
Chemical formulaC₂₆H₂₄F₃N₇O₃S
ReversibleY
Quality LevelMQ100
Applications
Biological Information
Primary TargetGLS1
Primary Target IC<sub>50</sub>23 nM & 28 nM, respectively, using murine kidney and brain homogenates
Purity≥97% by HPLC
Physicochemical Information
Cell permeableY
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Standard Handling
Storage +2°C to +8°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
5.33717.0001 04055977286656

Documentation

GLS1 Inhibitor III, CB-839 - CAS 1439399-58-2 - Calbiochem SDS

Title

Safety Data Sheet (SDS) 

GLS1 Inhibitor III, CB-839 - CAS 1439399-58-2 - Calbiochem Certificates of Analysis

TitleLot Number
533717

References

Reference overview
Gross, M.I., et al. 2014. Mol. Cancer Ther. 13, 890.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision26-August-2024 JSW
SynonymsN-(6-(4-(5-((2-Pyridin-2-ylacetyl)amino)-1,3,4-thiadiazol-2-yl)butyl)pyridazin-3-yl)-2-(3-(trifluoromethoxy)phenyl)acetamide, KGA Inhibitor III, 2-(Pyridin-2-yl)-N-(5-(4-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido)pyridazin-3-yl)butyl)-1,3,4-thiadiazol-2-yl)acetamide, GAC Inhibitor III, Kidney-Type Glutaminase Inhibitor III
DescriptionA cell-permeable thiadiazolyl-butyl-pyridazinyl compound that selectively inhibits GLS1 (IC50 = 23 nM & 28 nM, respectively, using murine kidney and brain homogenates), but not GLS2/LGA (up to 5 µM using murine liver homogenates), glutaminase activity in a non-competitive manner, being more potent than the uncompetitive GLS1 inhibitor BPTES, but with much slower inhibition kinetics (IC50/preincubation time ~300 nM/1 min & & 50 nM/1 h for CB-839; 630 nM/1 min & 700 nM/1 h for BPTES; 2 nM rhGAC aa 126-598) & reversibility (Activity recovery t1/2 after free drug removal = 45 min/CB-839 & <3 min/BPTES). CB-839 also displays higher antiproliferation potency than BPTES against triple negative breast cancer (TNBC) cultures (GI50 against MDA-MB-231 in 72 h = 19 nM vs. 2.4 µM with BPTES; GI50 against HCC1806 in 72 h = 55 nM vs. 2.0 µM with BPTES), while neither drug is effective against GLS1-independent growth of estrogen receptor-positive T47D even at 1 µM concentration. Despite a fast clearance in mice (Plasma t1/2 <2 h post 50 mg/kg p.o.), good drug exposure is reported in tumor and major organs (>1 nmol/g) 4 h post single 200 mg/10 mL/kg oral dosage among HCC1806 xenograft mice (Drug conc. = 2.1 µM in Plasma & 1.5 nmol/g in 500 mm3 tumor) except brain (~0.2 nmol/g) with most pronounced Glutamine buildup observed in tumor (5-fold) when compared to normal tissues (1- to 2.28-fold of of no treatment controls). Twice daily oral administration (200 mg/kg/12 h) is efficacious in suppressing the expansion of established tumor derived from HIMT-1 (by 54% in 35 d) and patient TNBC (by 59% in 28 d) and complete suppression of JIMT-1 tumor is seen when combined with 5 daily doses of Paclitaxel (10 mg/kg i.v.; Cat. Nos. 580555 & 580556) in the first 5 d of the treatment period.
FormYellow to brown solid
Intert gas (Yes/No) Packaged under inert gas
CAS number1439399-58-2
Chemical formulaC₂₆H₂₄F₃N₇O₃S
Purity≥97% by HPLC
SolubilityDMSO (25 mg/ml)
Storage Protect from light
+2°C to +8°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity Standard Handling
ReferencesGross, M.I., et al. 2014. Mol. Cancer Ther. 13, 890.